Form 8-K INTERCEPT PHARMACEUTICAL For: Mar 08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St indexes fall to two-week lows as rising bond yields, disappointing Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
H.C. Wainwright Upgrades Intercept Pharmaceuticals (ICPT) to Neutral
March 12, 2021 6:15 AM ESTH.C. Wainwright analyst Ed Arce upgraded Intercept Pharmaceuticals (NASDAQ: ICPT) from Sell to Neutral with a price target of $21.00 (from $25.00).
The analyst comments "We downgraded ICPT to Sell on February 23 when it traded at about $30 per share (prior close $29.86). The shares hit a multi-year low of $19.33 on March 4, and are now close to $21, largely on recent macroeconomic optimism, in our view. Our underlying thesis (NASH program has little to no risk-adjusted value, and PBC franchise faces substantial risks) has not changed. However, given the drop in... More
